

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Abemaciclib with an aromatase inhibitor for previously untreated locally advanced or metastatic hormone-receptor positive, HER2-negative breast cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No potential equality issues have been identified during the scoping process.

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No potential equality issues have been raise in the submissions, expert statements or academic report.
--

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No potential equality issues have been identified by the committee.

- | |
|--|
| 4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other |
|--|

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of Abemaciclib with an aromatase inhibitor for previously untreated locally advanced or metastatic hormone-receptor positive, HER2-negative breast cancer

Issue date: February 2019

groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

No.

Approved by Associate Director (name):Janet Robertson.....

Date: 02 October 2018

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of Abemaciclib with an aromatase inhibitor for previously untreated locally advanced or metastatic hormone-receptor positive, HER2-negative breast cancer

Issue date: February 2019

consultation, and, if so, how has the committee addressed these?

No, no equality issues have been raised during the consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

No.

Approved by Associate Director (name): ...Janet Robertson.....

Date: 07 December 2018

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of Abemaciclib with an aromatase inhibitor for previously untreated locally advanced or metastatic hormone-receptor positive, HER2-negative breast cancer

Issue date: February 2019